Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals

Background Aim was to determine the dynamics of peripheral blood mononuclear cells (PBMC)- associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the phenomenon. Methods Longitudinal, single-centre study measuring total HIV-1 DNA before the start of DAA, at the end of treatment (EOT), and 3 months after treatment. Univariable and multivariable analyses were used to assess factors associated with HIV-1 DNA increase ≥0.5 Log copies/million PBMC. Episomal 2-LTR forms, residual HIV-1 viremia and proviral DNA quasispecies evolution were also investigated. Results 119 successfully ART-treated HIV/HCV co-infected patients were included. Median baseline HIV-1 DNA was 3.84 Log copies/million PBMC (95%CI 3.49–4.05), and no significant variation with respect to baseline was found at EOT and after 3 months of DAA termination. In 17% of cases an increase ≥0.5 Log copies/million PBMC was observed at EOT compared to baseline. HIV-1 DNA increase was independently associated with lower baseline HIV-1 DNA, longer HIV suppression, raltegravir-based ART and previous exposure to interferon/ribavirin for HCV treatment. In none of the patients with HIV-1 DNA increase, 2-LTR forms were detected at baseline, while in 2 cases 2-LTR forms were found at EOT, without association with residual HIV-1 RNA viremia. No evidence of viral evolution was observed. Conclusions In successfully ART-treated HIV/HCV co-infected patients receiving DAA, PBMC-associated total HIV-1 DNA was quite stable over time, but some patients showed a considerable increase at EOT when compared to baseline. A significantly higher risk of HIV DNA increase was found, in presence of lower cellular HIV reservoir at baseline. Activation of replicative-competent virus generating new rounds of viral replication seems unlikely, while mobilization of cell-associated HIV from tissue reservoirs could be hypothesized.

[1]  V. Loustaud-Ratti,et al.  European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift , 2018, World journal of hepatology.

[2]  G. Palù,et al.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals , 2017, Medical Microbiology and Immunology.

[3]  G. Fogel,et al.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads , 2016, Journal of Virology.

[4]  B. Clotet,et al.  Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. , 2016, The Journal of infectious diseases.

[5]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[6]  P. Messiaen,et al.  HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. , 2015, The Journal of antimicrobial chemotherapy.

[7]  Nancie M Archin,et al.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.

[8]  David Rey,et al.  Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients , 2015, PloS one.

[9]  C. Charpentier,et al.  Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.

[10]  Rebecca J. Cope,et al.  Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. , 2015, AIDS patient care and STDs.

[11]  C. Rouzioux,et al.  Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Wei-jun Zhu,et al.  Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. , 2015, Antiviral research.

[13]  J. Mellors,et al.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Eric Jullian,et al.  Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial , 2014, AIDS Research and Therapy.

[15]  Xu G. Yu,et al.  Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. , 2014, The Journal of infectious diseases.

[16]  N. Ciccarelli,et al.  Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA , 2014, Journal of the International AIDS Society.

[17]  D. Cooper,et al.  HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.

[18]  C. Rouzioux,et al.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. , 2013, The Journal of antimicrobial chemotherapy.

[19]  M. Carrington,et al.  Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. , 2013, The Journal of infectious diseases.

[20]  G. Pantaleo,et al.  Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.

[21]  L. Montaner,et al.  Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials , 2012, AIDS.

[22]  D. Cooper,et al.  Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA , 2012, PloS one.

[23]  John W. Mellors,et al.  No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.

[24]  M. Capobianchi,et al.  Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  P. Narciso,et al.  Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart , 2011, Antiviral therapy.

[26]  W. Bradford,et al.  Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection , 2011, Antimicrobial Agents and Chemotherapy.

[27]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[28]  P. Narciso,et al.  Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  Olga M Klibanov,et al.  Integrase Inhibitors: A New Treatment Option for Patients with Human Immunodeficiency Virus Infection , 2008, Pharmacotherapy.

[30]  U. Pastorino,et al.  Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .

[31]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Rouzioux,et al.  Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level , 2003, AIDS.

[33]  M. Saag,et al.  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. , 1999, The Journal of clinical investigation.

[34]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[35]  G. Salama,et al.  Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[36]  J. Ball,et al.  Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. , 2002, The Journal of general virology.

[37]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.